|
A Study of LXR015-1 in HIV-Infected Patients Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Study of LXR015-1 in HIV-Infected Patients conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of LXR015-1 in HIV-Infected Patients Clinical research trials and A Study of LXR015-1 in HIV-Infected Patients health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Study of LXR015-1 in HIV-Infected Patients. A Study of LXR015-1 in HIV-Infected Patients Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Study of LXR015-1 in HIV-Infected Patients clinical trial. Subjects frequently get the best healthcare possible for their A Study of LXR015-1 in HIV-Infected Patients condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of LXR015-1 in HIV-Infected Patients  A Study of LXR015-1 in HIV-Infected Patients
A Study of LXR015-1 in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): LXR Biotechnology ,
Synopsis: To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients.
Details: Patients will be randomized to 1 of 3 doses of oral LXR015-1 for 28 days and patients will be monitored for adverse events for the duration of the study. Patients will continue to be monitored for least 4 weeks after completion of the dosing.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Documented HIV infection. - CD4 cell count less than 200 cells/mm3. Prior Medication: Allowed: Acute therapy for opportunistic infections or serious AIDS defining infections must be completed at least 28 days before study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Patients that are unable to take adequate oral intake (i.e. unable to eat 1 or more meals a day because of chronic nausea, emesis, or abdominal/oral/esophageal discomfort). - Patients who have severe diarrhea as defined as >= 7 stools per day, or acute diarrhea due to a treatable cause. NOTE: - If the patient has Cryptosporidia, Mycobacterium avium, or Cytomegalovirus that is unresponsive to treatment and has less than 7 stools per day, the patient may participate in this study. - Patients who have any severe or life-threatening laboratory or clinical abnormality, or are not expected to live for 8 weeks. - Patients who have an active opportunistic infection, including tuberculosis, cryptococcosis, or other serious AIDS defining infections requiring immediate treatment. Acute therapy must be completed at least 28 days before study entry. - Patients with unexplained elevated temperature >= 38.5 degrees C that persists for 7 days or more within 14 days before study entry. - Patients with malignancy other than squamous or basal carcinomas of the skin. Patients with visceral Kaposi's sarcoma or lymphoma requiring systemic chemotherapy or radiation treatment will be excluded. Patients with Kaposi's of the skin or mucous membranes may enroll in this study. - Patients, who in the judgment of the investigator are unable to comply with the protocol. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior condition are excluded: A known history of hypersensitivity reaction to soy protein or soy lecithin. NOTE: - This hypersensitivity is identified through medical history, not skin testing. Excluded: - Systemic chemotherapy. - Acute therapy for opportunistic infections or other serious AIDS defining infections. - Intravenous rehydration as treatment for diarrhea. Required: Patient must be taking a stable regimen (about 8 weeks) of anti-viral, anti-opportunistic infection and/or anti-diarrheal (if patient has diarrhea) medications.
Total Enrollment: 30
Location and Contact Information:
Overall Study Official:
BathurstI, Study Chair,
East Bay AIDS Ctr
Berkeley, California, 94705
United States
Additional Information:
Study ID Numbers: 258A;
Study Start Date:
Record last reviewed: July 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002365
Other Hiv Infections Studies:
1. Underlying abnormalities in fat and muscle leading to Lipodystrophy Syndrome
2. Immune Response to Influenza Vaccine in HIV-Infected Individuals
3. A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
4. Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients with HIV and Hepatitis C Virus
5. A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients with AIDS Who Take Daily Multivitamin and Mineral Supplements
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other Berkeley Clinical Trials
A Study of LXR015-1 in HIV-Infected Patients
|
|
|
|
|
|
|
|
